TEE
TBPH icon

Tibra Equities Europe’s Theravance Biopharma TBPH Stock Holding History

Tibra Equities Europe’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-29,100
Closed -$660K – 418
2019
Q1 		$660K Buy
+29,100
New +$738K 0.07% 232

Other funds holding TBPH

WIM
Woodford Investment Management London, United Kingdom $310M AUM 17.41% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Tibra Equities Europe's TBPH Position: Q2 2019 in Review

Tibra Equities Europe sold out of Theravance Biopharma (TBPH) in Q2 2019, closing a stake of 29,100 shares — an estimated $660K sold.

Tibra Equities Europe first reported a position in TBPH in Q1 2019 and held it in 1 quarter. The position peaked at $660K in Q1 2019. 98 funds tracked by Wall St. Rank hold TBPH as of Q2 2019.

  • Tibra Equities Europe reported no remaining Theravance Biopharma position as of Q2 2019 after selling out during the quarter.
  • Tibra Equities Europe sold 29,100 Theravance Biopharma shares in Q2 2019, an estimated $660K.
  • Tibra Equities Europe first reported a position in Theravance Biopharma in Q1 2019 and held it in 1 quarter.
  • Tibra Equities Europe's Theravance Biopharma position peaked at $660K in Q1 2019.
  • 98 funds tracked by Wall St. Rank held Theravance Biopharma as of Q2 2019.

Based on Tibra Equities Europe's 13F filing for Q2 2019, filed 1 Aug 2019.